The preprint asks how the composition of weight loss differs between medicines, extending the focus beyond total kilograms lost.
This suggests that patients shouldn’t simplistically be thinking, ‘I want to lose X amount of weight and I’ll go with the option that delivers greater weight loss’
Dose and weight change show different associations with cardiovascular outcomes in a real-world landmark analysis.
These findings suggest a cardioprotective role of semaglutide which may be related to attained dose but is not explained simply by the amount of weight loss achieved while on therapy
A managed-care report on the clinical-note analysis of more than 1,000 BPC-157 users, which found rising off-label use for pain and healing while outcomes remain unproven.
A brief news summary: hormone therapy was linked to greater and sustained weight loss with semaglutide, while the early difference with tirzepatide was not statistically significant.
In a preprint of 572 pregnancies with semaglutide prescribed before conception, complications, preterm birth, stillbirth and newborn Apgar scores did not differ between women who continued the drug and those who stopped.
These observations motivate the need for larger retrospective and prospective studies to rigorously establish the safety of semaglutide exposure during pregnancies
A clinical news report on the presentation: greater weight loss with semaglutide alongside hormone therapy, a smaller and short-lived difference with tirzepatide, and the study’s limits for primary care.
A look at documented use and the limits of observational comparisons.
This pattern suggests that at least some patients received a biologically active product capable of producing incretin-like cardiovascular pharmacology, but without the degree of weight-loss efficacy observed under a clinical-trial protocol
In a real-world study of oral semaglutide, patients whose weight gain was recent were more likely to respond strongly; the findings are observational and preliminary.
A dental trade report on a preprint of oral and dental conditions after semaglutide or tirzepatide, with an outside caution against reading association as causation.
While xerostomia deserves our attention, this early research is also an important reminder not to confuse association with causation or assume that GLP-1 use inherently leads to dental disease
Pamela Maragliano, chief editor of Dental Economics — not involved in the study
Women on menopause hormone therapy lost more weight on semaglutide in a large real-world cohort presented at The Menopause Society; the signal was weaker with tirzepatide and needs prospective confirmation.
These findings need to be confirmed in adequately designed prospective trials, and it’s important to remember that weight loss is not an indication for menopause hormone therapy
Regina Castaneda, Mayo Clinic Florida, lead researcher
The lead researcher explains why hormone therapy was linked to greater weight loss with semaglutide but not clearly with tirzepatide, and why the results are hypothesis-generating.
While encouraging, these results should be viewed as hypothesis-generating
Regina Castaneda, Mayo Clinic Florida, lead researcher
Patients who stayed on starter doses still lost weight in the real-world comparison; an outside surgeon describes seeing the same in practice.
I have seen this in my own practice. Although these starter doses are generally intended to help patients adjust to the medication, some people may experience meaningful weight loss even at these lower doses
A clinical summary of the study: hormone therapy may be linked to greater weight loss with semaglutide, but the findings are observational and no reason to prescribe hormone therapy for weight management.
We are seeing a consistent signal
Regina Castaneda, Mayo Clinic Florida, lead researcher
Broadcast coverage of healing claims draws on the analysis of 1,039 documented users and outside cautions about untested peptides.
People need to understand that there’s a huge difference between peptides that have been rigorously studied and approved as medications, such as insulin and GLP-1 weight-loss drugs, and these newer compounds
Christopher Robinson, Johns Hopkins University School of Medicine
A clinical briefing puts uncommon hair-loss signals into context and highlights questions for further investigation.
Clinicians may consider discussing the possibility of hair loss when initiating GLP-1 receptor agonist therapy and monitoring for symptoms during follow-up, particularly in the first year
Women taking semaglutide with hormone therapy lost a few more pounds on average than those without it; the lead researcher and an outside ob-gyn put the observational finding in context.
Our earlier, smaller studies showed an association between hormone therapy use and greater weight loss in postmenopausal women, and the fact that we see the same signal in a larger, independent cohort should not be overlooked
Regina Castaneda, Mayo Clinic Florida, lead researcher
The Menopause Society’s release on the study: hormone therapy was linked to greater and sustained weight loss with semaglutide, with results differing by type of GLP-1.
These findings suggest that hormone therapy may influence how some women respond to GLP-1-based weight loss medications
Stephanie Faubion, The Menopause Society; study co-author
Clinical notes document BPC-157 use in 1,039 patients. Incomplete, confounded outcomes cannot establish safety or effectiveness.
There was no placebo or untreated comparator, and there was no standardized indication, formulation, dose, route, treatment duration, or outcome assessment
Flynn McGuire, University of Utah — not involved in the study · The Independent
Higher attained semaglutide dose, not the amount of weight lost, tracked with fewer new neuropsychiatric diagnoses in the published observational study.
The weighing scale may tell only part of the story when it comes to GLP-1 medicines
Coverage of an observational preprint examining weight trajectories and cardiovascular symptoms among documented retatrutide users.
The study provides an important signal that patients are obtaining unapproved retatrutide through unregulated channels, where the product, dose, purity, manufacturing quality, safety, and efficacy cannot be reliably verified
Priya Jaisinghani, NYU Langone Health — not involved in the study
Outside clinicians discuss uncommon frailty-related events and the importance of interpreting early findings in the context of overall treatment benefits.
The study showed that risk was associated with level of weight loss while also highlighting other important factors such as malnutrition and dehydration. However, the paper did not show that tirzepatide was not safe and, as with many studies, limitations to the research did occur
Kristin Kirkpatrick, Cleveland Clinic — not involved in the study
The lean-mass preprint suggests that greater weight loss with tirzepatide may come with more lean tissue lost; an outside surgeon is not surprised.
This finding is not entirely surprising. Tirzepatide is generally more potent than semaglutide, and with greater overall weight loss, you often see a higher degree of lean mass loss as well
Jeffrey Lee, JL Plastic Surgery — not involved in the study
C. Michael Gibson, MDHarvard Medical School · Baim Institute
“These studies from nference signal that longitudinal, AI-curated evidence can inform prospective studies in profound ways. The broad spectrum of weight-loss-independent benefits revealed by the first series of MAIA publications challenges long-held cardiometabolism assumptions that place glucose lowering and total body weight reduction at the center of therapeutic value. These findings reinforce that incretin biology is organ-specific, durable, and multidimensional.”
“What makes this study interesting is that even after researchers matched patients for how much weight they lost, hair loss remained somewhat more common with tirzepatide: 4.24 percent versus 3.33 percent. That suggests weight loss may not be the entire explanation.”
“The weighing scale may be the loudest biomarker of GLP-1 therapy effectiveness, but the heart may be reading a distinct signal of therapeutic benefit. If confirmed prospectively, this finding argues that cardiovascular trials should treat dose exposure, persistence, and organ endpoints as first-class variables rather than assuming weight loss is the major mediator.”
“Since the tirzepatide affects more than one receptor, it may have a greater impact on the body than just weight loss. GIP receptors have been identified in the hair follicles and, as the drug binds to these receptors, it may have an effect on the microenvironment surrounding the hair follicles, impacting their activity.”
“The recent publications from nference provide a new roadmap of AI-curated evidence that will almost certainly be used to inform gold standard randomized clinical trials for disorders beyond obesity and type 2 diabetes mellitus.”
Reuters’ account of her comments, not a direct quote
The reduction in lean body mass that accompanies GLP-1-induced weight loss may matter more in older patients because many start with low muscle reserve, said UCLA endocrinologist Dr. Preethi Srikanthan, who was not involved in the research. Whether tirzepatide-associated weight loss leads to clinically important frailty in vulnerable older adults needs to be verified with prospective data and gold-standard frailty assessment methods, she said.
“This may be the first time that decades of body-weight history have been reconstructed from routine patient records at this scale. The finding that GLP-1 super-responders are often the same patients who experienced the most recent acceleration in weight gain is a fundamental observation. It suggests that future cardiometabolism trials should not only ask how much weight a drug reduces, but whether the patient’s prior weight-gain velocity predicts the magnitude, durability, and clinical meaning of response.”
“These conditions are rare occurrences, and we should just be more aware of the issues for older adults. By no means does it mean we should not prescribe these medications to people over 65.”
“Interestingly, the effect was stronger with semaglutide than with tirzepatide, which deserves further study and may point to an interaction specific to GLP-1 signaling.”
Manish Kohli, MDHuntsman Cancer Institute · University of Utah
“For decades, oncology has studied tumor metabolism, but we have not fully leveraged the patient’s own metabolic trajectory as a clinical signal. These cancer metabotyping studies point to a common hypothesis: host metabolism may influence cancer progression, treatment tolerance, immune response, drug efficacy, and survival in ways that are measurable in routine care. If validated prospectively, weight trajectory and metabolic context could become practical tools for stratifying patients across solid tumors and hematologic malignancies.”
C. Michael Gibson, MDHarvard Medical School · Baim Institute
“The analysis gives us a little more hope that there are going to be some people who will not regain weight, that it’s not a lifelong treatment in everyone. We need to better identify who’s going to be successful.”
“The very promising link of microdose levels of these agents to lower 24-month event-rates for a broad array of cardiovascular endpoints despite very modest weight loss, when taken together with evidence of disproportionate lean muscle loss at higher doses of some agents, only emphasizes the reality that the magnitude and scope of the many and varied impacts of these agents are well beyond their effectiveness at overall weight loss.”
“Weight loss is linked to hair loss, especially when it’s fast or dramatic”, says Susan Massick, MD, a board-certified dermatologist at The Ohio State University Wexner Medical Center. “GLP-1s are known for helping people to lose weight quickly, which can explain why some patients on tirzepatide and semaglutide were faced with hair loss.”